This product complies with FDA guidelines, notably 21 CFR Part 1271, emphasizing their role as protective barriers that maintain elasticity, mirroring the amniotic tissue’s natural function. The decellularization process employs supercritical CO2 technology, which maintains the amniotic membrane’s structure and function, thus optimizing its therapeutic efficacy.

EpiPatch’s thinness, less than 0.1 mm, allows it to serve as a bioactive wound dressing that adheres upon contact, simplifying postoperative care, and is valued for its ease of use and storage.

Learn more about our product by visiting https://biomed-ent.com/epipatch or Contact Us for a consultation with our team!